G-protein coupled receptor signaling in myocardium: Not for the faint of heart

Physiology

Volumn 22, Issue 3, 2007, Pages 174-184

  Kang, Misuk ^a   Ka, Young Chung ^a   Walker, Jeffery W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR;

ANIMAL; HEART; HEART CONTRACTION; HEART DISEASE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HEART; HEART DISEASES; HUMANS; MYOCARDIAL CONTRACTION; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 34447503837     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00051.2006     Document Type: Review

References (108)

1. Abozguia K, Clarke K, Lee L, Frenneaux M. Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med 3: 490-498, 2006.
2. Adorisio R, DeLuca L, Rossi J, Gheorghiade M. Pharmacological treatment of chronic heart failure. Heart Failure Rev 11: 109-123, 2006.
3. Angerio AD. The role of endothelin in heart failure. Crit Care Nurs Quart 28: 355-359, 2005.
4. Balijepalli RC, Lokuta AJ, Maertz NA, Buck JM, Haworth RA, Valdivia HH, Kamp TJ. Depletion of T-tubules and specific subcellular changes in sarcolemmal proteins in tachycardia-induced heart failure. Cardiovasc Res 59: 67-77, 2003.
5. Battistini B, Daull P, Jeng AY. CGS 35601, a triple inhibitor of angiotensin II converting enzyme, neutral endopeptidase and endothelin converting enzyme. Cardiovasc Drug Rev 23: 317-330, 2005.
6. Bauersachs J, Schafer A. Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches. Curr Vasc Pharmacol 2: 115-124, 2004.
7. Borlak J, Thum T. Hallmarks of ion channel gene expression in end-stage heart failure. FASEB J 17: 1592-1608, 2003.
8. Bootman MD, Hiqazi DR, Coombes S, Roderick HL. Calcium signaling during excitation-contraction coupling in mammalian atrial myocytes. J Cell Sci 119: 3915-3925, 2006.
9. Braz JC, Bueno OF, De Windt LJ, Molkentin JD. PKC-alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2). J Cell Biol 156: 905-919, 2002.
10. Brette F, Orchard C. T-tubule function in mammalian cardiac myocytes. Circ Res 92: 1182-1192, 2003.
11. Brittsan AG, Kranias EG. Phospholamban and cardiac contractile function. J Mol Cell Cardiol 32: 2131-2139, 2000.
12. Brodde OE, Bruck H, Leinweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharm Sci 100: 323-337, 2006.
13. Cheng CP, Ukai T, Onishi K, Ohte N, Suzuki M, Zhang ZS, Cheng HJ, Tachibana H, Igawa A, Little WC. The role of ANG II and endothelin-1 in exercise induced diastolic dysfunction in heart failure. Am J Physiol Heart Circ Physiol 280: H1853-H1860, 2001.
14. Clerk A, Sugden PH. Activation of protein kinase cascades in the heart by hypertrophic G protein-coupled receptor agonists. Am J Cardiol 83: 64H-69H, 1999.
15. Corder R, Mullen W, Khan NQ, Marks SC, Wood EG, Carrier MJ, Crozier A. Red wine procyanidins and vascular health. Nature 444: 566, 2006.
16. Dawn B. Preconditioning by angiotensin II: a tale of more than two kinases. J Mol Cell Cardiol 41: 223-225, 2006.
17. Devi LA. Heterodimerization of G-protein coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol Sci 22: 532-537, 2001.
18. Dorn GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115: 527-537, 2005.
19. Dzimiri Receptor crosstalk N. Implications for cardiovascular function, disease and therapy. Eur J Biochem 269: 4713-4730, 2002.
20. Floras JS. Sympathetic activation in human heart failure: diverse mechanisms, therapeutic opportunities. Acta Physiol Scand 177: 391-398, 2003.
21. Fraccarollo D, Hu K, Galuppo P, Guadron P, Ertl G. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 96: 3963-3973, 1997.
22. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad and the ugly. Annu Rev Physiol 65: 45-79, 2003.
23. Gabbay E, Reed A, Williams TJ. Assessment of treatment of pulmonary arterial hypertension: an Austrialian perspective in 2006. Intern Med 37: 38-48, 2007.
24. Gibbs CL, Barclay CJ. Cardiac efficiency. Cardiovasc Res 30: 627-643, 1995.
25. Gourine AV, Molosh AI, Poputnikov D, Bulhak A, Sjoquist PO, Pernow J. Endothelin-1 exerts a preconditioning-like cardioprotective effect against ischaemia/reperfusion injury via the ET(A) receptor and mitochondrial K(ATP) channel in the rat. Br J Pharmacol 144: 331-337.
26. Hasenfuss G, Mulieri LA, Allen PD, Just H, Alpert NR. Influence of isoproterenol and ouabain on excitation-contraction coupling, cross-bridge function, and energetics in failing human myocardium. Circulation 94: 3155-3160, 1996.
27. 2+ current by activation of protein kinase C in rat ventricular myocytes. J Physiol 524: 807-820, 2000.
28. Henegar JR, Brower GL, Kabour A, Janicki JS. Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. Am J Physiol Heart Circ Physiol 269: H1564-H1569, 1995.
29. Hou Y, Yang J, Price EE, Gleaves L, Eren M, Ni G, Yang Y, Zhu WZ, Joiner M, Zhang R, Oddis CV, Vaughan DE, Xiao RP, Anderson ME. Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo. Am J Physiol Heart Circ Physiol 291: H3065-H3075, 2006.
30. Hulme JT, Westenbroek RF, Scheuer T, Catterall WA. Phosphorylation of serine 1928 in the distal C-terminal domain of CaV1.2 channels during beta1-adrenergic regulation Proc Natl Acad Sci USA 103: 16574-16579, 2006.
31. Iwanaga Y, Kihara Y, Inagaki K, Onozawa Y, Yoneda T, Kataoka K, Sasayama S. Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation 104: 606-612, 2001.
32. Iwanaga Y, Kihara Y, Hasegawa K, Inagaki K, Yoneda T, Kaburagi S, Araki M, Sasayama S. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation 98: 2065-2073, 1998.
33. Jacobs A, Preston IR, Gomberg-Maitland M. Endothelin receptor antagonism in pulmonary arterial hypertension-a role for selective ETA inhibition? Curr Med Res Opin 22: 2567-2574, 2006.
34. Kaye D, Esler M. Sympathetic neuronal regulation of the heart in aging and heart failure. Cardiovasc Res 66:256-264, 2005.
35. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs, Anversa P. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 29: 859-870, 1997.
36. Kakita T, Hasegawa K, Iwai-Kanai E, Adachi S, Morimoto T, Wada H, Kawamura T, Yanazume T, Sasayama S. Calcineurin pathway is required for endothelin-1-mediated protection against oxidant stress apoptosis in cardiac myocytes. Circ Res 88: 1239-1246, 2001.
37. Kang M, Walker JW. Protein kinase C delta and epsilon mediate positive inotropy in adult ventricular myocytes. J Mol Cell Cardiol 38: 753-764, 2005.
38. Kang M, Walker JW. Endothelin-1 and PKC induce positive inotropy without affecting pHi in ventricular myocytes. Exp Biol Med 231: 865-870, 2006.
39. Kedzierski RM, Yanagisawa M. Endothelin system: the double edged sword in health and disease. Annu Rev Pharmacol Toxicol 41: 851-876, 2001.
40. Kedzierski RM, Grayburn PA, Kisanuki YY, Williams CS, Hammer RE, Richardson JA, Schneider MD, Yanagisawa M. Cardiomyocyte specific endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol. Mol Cell Biol 23: 8226-8232, 2003.
41. Kelland NF, Webb DJ. Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med 231: 696-699, 2006.
42. Keys JR, Kock WJ. The adrenergic pathway and heart failure. Recent Prog Horm Res 59: 13-30, 2004.
43. Khan MH, Sinoway LI. Muscle reflex control of sympathetic nerve activity in heart failure: the role of exercise condition. Heart Failure Rev 5: 87-100, 2000.
44. Khattar KS. Effect of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure. Minerva Cardioangiol 51: 143-154, 2003.
45. Lee TM, Lin MS, Chou TF, Chang NC. Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats. Am J Physiol Heart Circ Physiol 291: H1281-H1289, 2006.
46. Lenhart SE, Terrenoire C, Reiken S, Wehrens XH, Song LS, Tillman EJ, Mancarella S, Coromilas J, Lederer WJ, Kass RS, Marks AR. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias. Proc Natl Acad Sci USA 103: 7906-7910, 2006.
47. MacCarthy PA, Grocott-Mason R, Prendergast BD, Shah AM. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ETA receptor antagonist. Circulation 101: 142-147, 2000.
48. McClellan G, Weisberg A, Winegrad S. Effect of endothelin-1 on actomyosin ATPase activity. Implications for the efficiency of contraction. Circ Res 78: 1044-1050, 1996.
49. Molenaar PV, Parsonage WA. Fundamtnetal considerations of β-adrenoceptor subtypes in human heart failure. Trends Pharmacol Sci 26: 368-375.
50. Mollman H, Schmidt-Schewda S, Nef H, Mollman Burstin JV, Klose S, Elsasser A, Holubarsch CJF. Contractile effects of angiotensin and endothelin in failing and non-failing human hearts. Int J Cardiol 114: 43-40, 2007.50.
51. Morawietz H, Goettsch W, Szibor M, Barton M, Shaw S, Hakim K, Zerkowski HR, Holtz J. Angiotensin II converting enzyme inhibitor therapy prevents upregulation of endothelin converting enzyme-1 in failing human myocardium. Biochem Biophys Res Commun 295: 1057-1061, 2002.
52. Motte S, van Beneden R, Mottet J, Rondelet B, Mathieu M, Havaux X, Lause P, Clercx C, Ketelslegers JM, Naeije R, McEntee K. Early activation of cardiac and renal endothelin systems in experimental heart failure. Am J Physiol Heart Circ Physiol 285: H2482-H2491, 2003.
53. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Mace B, Conoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure: effect of long term treatment with an endothelin antagonist on survival, hemodynamics and cardiac remodeling. Circulation 96: 1976-1982, 1997.
54. Munzel F, Muhlhaauser U, Zimmermann WH, Didie M, Schneiderbanger K, Schubert P, Engmann S, Eschenhagen. Endothelin-1 and isoprenaline co-stimulation causes contractile failure which is partially reversed by MEK inhibition. Cardiovasc Res 68: 464-474, 2005.
55. Nerbonne JM, Kass RS. Molecular physiology of cardiac reporlarization. Physiol Rev 85: 1205-1253, 2005.
56. O'Connell TD, Swigart PM, Rodrigo MC, Ishizaka S, Joho S, Turnbull L, Tecott LH, Baker AJ, Forster E, Grossman W, Simpson PC. Alpha1-adrenergic receptors prevents a maladaptive cardiac response to pressure overload. J Clin Invest 116: 1005-1015, 2006.
57. Ogata Y, Takahashi M, Ueno S, Takeuchi S, Okada T, Mano H, Ookawara S, Ozawa K, Berk BC, Ikeda U, Shimada K, Kobayashi E. Antiapoptotic effect of endothelin-1 in rat cardiomyocytes in vitro. Hypertension 41: 1156-1163, 2003.
58. Onishi K, Ohno M, Little WC, Cheng CP. Endogenous endothelin-1depresses left ventricular systolic and diastolic performance in congestive heart failure. J Pharmacol Exp Ther 288: 1214-1222, 1999.
59. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodeling. Lancet 367: 356-67, 2006.
60. Packer M. Neurohumoral hypothesis: a theory to explain mechanisms of disease progression in heart failure. J Am Coll Cardiol 20: 248-254, 1992.
61. Perrino D, Esposito G, Rockman HA. Defects in cardiomyocyte function: role of beta-adrenergic receptor dysfunction. Panminerva Med 47: 143-155, 2005.
62. Pi YQ, Kemnitz KR, Zhang D, Kranias EG, Walker JW. Phosphorylation of troponin I controls cardiac twitch dynamics. Circ Res 90: 649-656, 2002.
63. 2+ sensitivity and ATPase activity in the mouse myocardium. J Physiol 552, 845-857, 2003.
64. Ping P, Zhang J, Cao X, Li RC, Kong D, Tang XL, Qiu Y, Manchikalapudi S, Auchampac JA, Black RG, Bolli R. PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits. Am J Physiol Heart Circ Physiol 276: H1468-H1481, 1999.
65. Ponicke K, Vogelsang M, Heinroth M, Becker K, Zolk O, Bohm M, Zerkowski HR, Brodde OE. Endothelin receptors in the failing and non-failing heart. Circulation 97: 744-751, 1998.
66. Riksen NP, Smits P, Rongen GA. Ischaemic preconditioning: from molecular characterization to clinical application: part I. J Med 62: 353-363, 2004.
67. Ritter O, Neyses L. The molecular basis of myocardial hypertrophy and heart failure. Trends in Mol Med 9: 313-321, 2003.
68. Robu VG, Pfeiffer ES, Robia SL, Balijepalli RC, Pi Y, Kamp TJ, Walker JW. Localization of functional endothelin receptor signaling complexes in cardiac transverse tubules. J Biol Chem 278: 48154-48161, 2003.
69. Rozec B, Gauthier C. Beta3-adrenoceptors in the CV system: putative pathological role in human pathologies. Pharmacol Ther 111: 652-673, 2006.
70. Sadoshima J, Xu Y, Slater HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75: 977-984, 1993.
71. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Shugishita. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384: 353-355, 1996.
72. Shah AM. Decreased myocardial contractility after damage to endocardial endothelium is caused mainly by loss of endothelin production. Cardiovasc Res 30: 644-645, 1995.
73. Shiojima I, Sato k Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115: 2108-2118, 2005.
74. Singh K, Xiao L, Remondino A, Sawyer DB, Colucci WS. Adrenergic regulation of cardiac myocyte apoptosis. J Cell Physiol 189: 257-265, 2001.
75. Sucharoa CC, Mariner PD, Nunley KR, Long C, Leinwand L, Bristow MR. A beta1-adrenergic receptor CAM kinase II dependent pathway mediates cardiac myocyte fetal gene expression. Am J Physiol Heart Circ Physiol 291: H1299-H1308, 2006.
76. Suga H. Ventricular energetics. Physiol Rev 70: 247-277, 1990.
77. Suzuki M, Ohte N, Wang ZM, Williams DL Jr, Little WC, Cheng CP. Altered inotropic response of endothelin-1 in cardiomyocytes from rats with isoproterenol-induced cardiomyopathy. Cardiovasc Res 39: 589-599, 1998.
78. Takeuchi Y, Kihara Y, Inagaki K, Yoneda T, Sasayama S. Endothelin-1 has a unique oxygen-saving effect by increasing contractile efficiency in the isolated rat heart. Circulation 103: 1557-1563, 2001.
79. Tang CM, Insel PA. GPCR expression in the heart: "new" receptors in myocytes and fibroblasts. Trends Cardiovasc Med 14: 94-99, 2004.
80. Teerlink JR. Endothelins: pathophysiology and treatment implications in chronic heart failure. Curr Heart Failure Rep 2: 191-197, 2005.
81. Thai HM, Do BQ, Tran TD, Gaballa MA, Goldman S. Aldosterone antagonism improves endothelial-dependence vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail 12: 240-245, 2006.
82. Thomas PB, Liu EC, Webb ML, Mukherjee R, Hebbar L, Spinale FG. Exogenous effects and endogenous production of endothelin in cardiac myocytes: potential significance in heart failure. Am J Physiol Heart Circ Physiol 271: H2629-H2637, 1996.
83. Tonnesson T, Knudsen CW. Surgical left ventricular remodeling in heart failure. Eur J Heart Failure 7: 704-709, 2005.
84. Touyz RM, Reudelhuber TL, Schiffrin EL, Amiri F, Virdis A, Neve MF, Iglarz M, Seidah NG. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110: 2233-2240, 2004.
85. Tsuruda T, Jougasaki M, Boerrigter G, Huntley BK, Chen HH, D'Assoro AB, Lee SC, Larsen AM, Cataliotti A, Burnett JC. Cardiotropin-1 stimulation of cardiac fibroblast growth. Roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res 90: 128-134, 2002.
86. 2-adrenergic receptor proliferation of human cardiac fibroblasts. FEBS Lett 576: 156-160, 2004.
87. Vikstrom KL, Bohlmeyer T, Factor SM, Leinwand LA. Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circ Res 82: 773-778, 1998.
88. Wainright CL, McCabe C, Kane KA. Endothelin and the ischaemic heart. Curr Vasc Pharmacol 3: 333-341, 2005.
89. Walker JW. Kinetics of the actin-myosin interaction. In: Handbook of Physiology: The Cardiovascular System. The Heart. Bethesda, MD: Am. Physiol. Soc., 2002, sect. 2, vol. I, chapt. 6, p. 240-263.
90. Walker CA, Ergul A, Grubbs A, Zile MR, Zellner JL, Crumbley AJ, Spinale FG. Beta-adrenergic and endothelin receptor interaction in dilated cardiomyopathic myocardium. J Card Fail 7: 129-137, 2001.
91. 2+ by phosphorylating troponin I on threonine-144. J Mol Cell Cardiol 41: 823-833, 2006.
92. Wang W, Ma R. Cardiac sympathetic afferent reflexes in heart failure. Heart Failure Rev 5: 51-57, 2000.
93. 2+/calmodulin kinase signaling pathway. Circ Res 95: 798-806, 2004.
94. Watson AM, Hood SG, May CN. Mechanisms of sympathetic activation in heart failure. Clin Exp Pharmacol Physiol 33: 1269-1274, 2006.
95. White RM. The role of brain natriuretic peptide in systolic heart failure. Dimens Crit Care Nurs 24: 171-174, 2005.
96. Xia Y, Karmazyn M. Obligatory role for endogenous endothelin in mediating the hypertrophic effects of phenylephrine and angiotensin II in neonatal rat ventricular myocytes: evidence for two distinct mechanisms for endothelin regulation. J Pharmacol Exp Ther 310: 43-51, 2004.
97. Xu Z, Mueller RA, Park SS, Boysen PG, Cohen MV, Downey JM. Cardioprotection with adenosine A2 receptor at reperfusion. J Cardiovasc Pharmacol 46: 794-802, 2005.
98. Yamauchi-Kohno R, Miyauchi T, Hoshino T, Kobayashi T, Aihara H, Sakai S, Yabana H, Goto K, Sugishita Y, Murata S. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Circulation 99: 2171-2176, 1999.
99. Yang LL, Gros R, Kabir MG, Sadi A, Gotlieb AI, Husain M, Stewart DJ. Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation 109: 255-261, 2004.
100. Yee DK, Suzuki A, Luo L, Fluharty SJ. Identification of structural determinants for G protein independent activation of mitogen-activated protein kinases in the seventh transmembrane domain of the angiotensin II type 1 receptor. Mol Endocrinol 20: 1924-1934, 2006.
101. Yoshiyama M, Nakamura Y, Omura T, Matsumoto R, Oda S, Takeuchi K, Kim S, Iwao H, Yoshikawa J. Angiotensin converting enzyme inhibitor prevents left ventricular remodeling after myocardial infarction in angiotensin II receptor knockout mice. Heart 91: 1080-1085, 2005.
102. 1 receptor mutant lacking Gαq/Gαi coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 115: 3045-3056, 2005.
103. Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr, Thiel W, Guatimosim S, Song LS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 11: 409-417, 2005, 2005.
104. 2+-calmodulin dependent protein kinase II in cardiac hypertrophy and heart failure. Cardiovasc Res 63: 476-486, 2004.
105. Zhao XS, Pan W, Bekeredjian R, Shohet RV. Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation 114: 830-837, 2006.
106. 2+/calmodulin- dependent kinase II and calcineurin play critical roles in endothelin-1-induced cardiomyocyte hypertrophy. J Biol Chem 275: 15239-15245, 2000.
107. 2+/calmodulin kinase II. J Clin Invest 111: 617-625, 2003.
108. Zou Y, Hiroshi A, Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, Makita N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagai T, Fukamizu Umemura S, Iiri T, Fujita T, Komuro I. Mechanical stress activates angiotensin II type receptor without involvement of angiotensin II. Nat Cell Biol 6: 499-506, 2004.